No Data
Express News | PDS Biotechnology Corp - Biotech to Initiate Versatile-003 Phase 3 Trial in Q1 2025
Express News | PDS Biotech Reaffirms Guidance for First Quarter Initiation of Versatile-003 Phase 3 Clinical Trial in Hpv16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A. G. P. Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Cuts Target Price to $4.5
Express News | HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Promising Advancements in Cancer Treatment Drive Buy Rating for PDS Biotechnology
